Condition: B-cell Acute Lymphoblastic Leukemia · B-cell Non Hodgkin Lymphoma · Sponsor: University of Colorado, Denver
This phase I/II trial will investigate a new CD19 directed CAR-T therapy manufactured locally with the goals to expedite infusion to wider patient inclusion that includes those who were previously excluded, such as pediatric patients with B-cell NHL and patients in primary relapse.
This description comes directly from the study's public registry record.
Vanessa Fabrizio, MD, MS · 720-777-6860 · BMT@childrenscolorado.org
Kayla Ortiz · 720-777-2564 · kayla.ortiz@childrenscolorado.org
Always discuss trial participation with your own doctor first.
| Children's Hospital Colorado | Aurora, Colorado, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04544592